What is HC Wainwright’s Forecast for AXSM Q1 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued to investors on Thursday, February 20th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of $0.11 per share for the quarter. HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ FY2026 earnings at $7.52 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.

Several other equities analysts have also issued reports on AXSM. Wells Fargo & Company boosted their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Truist Financial lifted their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners lifted their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC boosted their target price on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.79.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $137.75 on Friday. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. The business’s 50 day moving average price is $101.29 and its two-hundred day moving average price is $94.91. The firm has a market cap of $6.72 billion, a PE ratio of -23.00 and a beta of 1.05.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL boosted its holdings in Axsome Therapeutics by 32.7% during the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after purchasing an additional 342,064 shares during the last quarter. FMR LLC boosted its stake in Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the last quarter. Geode Capital Management LLC boosted its stake in Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock valued at $77,228,000 after acquiring an additional 4,079 shares during the last quarter. Wellington Management Group LLP boosted its stake in Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Axsome Therapeutics by 10.8% in the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock valued at $58,589,000 after acquiring an additional 67,285 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.